Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tango Therapeutics, Inc.TNGX · Entity 1497 | Chief Scientific Officer | March 01, 2023 | March 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tango Therapeutics, Inc.
Report date March 01, 2023 · Filed March 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 167,584 |
Reported balance
After 2023-03-01 transaction · row 1
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 31,697 · Balance 167,584 F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 1/3 on February 5, 2024, 1/3 on February 3, 2025 and 1/3 on February 2, 2026 subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.20 · Expires 2033-03-01 | Direct | 190,181 |
Reported balance
After 2023-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-01 · Grant · Acquired 190,181 · Balance 190,181 F2: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 1/3 on February 5, 2024, 1/3 on February 3, 2025 and 1/3 on February 2, 2026 subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Mar 2, 2023 16:05 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 190,181 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0000899243-23-006728 · doc4.xml · derivative · entry 2 Huang Alan · CIK 0001877364 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,181 Underlying: Common Stock · 190,181 shares Expires 2033-03-01 F2 · derivative.exercise_date: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 16:05 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 31,697 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-006728 · doc4.xml · nonDerivative · entry 1 Huang Alan · CIK 0001877364 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,584 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 1/3 on February 5, 2024, 1/3 on February 3, 2025 and 1/3 on February 2, 2026 subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 16:30 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $9.22 | $0.00 |
DisclosureSEC source: 0000899243-22-004603 · doc4.xml · derivative · entry 1 Huang Alan · CIK 0001877364 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2023, with the remaining option shares vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 19:00 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 169,859 | $0.00 Strike: $9.56 | $0.00 |
DisclosureSEC source: 0000899243-21-033151 · doc4.xml · derivative · entry 1 Huang Alan · CIK 0001877364 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,859 Underlying: Common Stock · 169,859 shares Expires 2031-08-12 F1 · derivative.exercise_date: This option shall vest and become exercisable over a four-year period, at a rate of 25% on August 10, 2022, with the remaining option shares vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.